Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
D 10.98 1.20% 0.13
SGMO closed up 4.33 percent on Friday, May 14, 2021, on 65 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical SGMO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.20%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.58%
Outside Day Range Expansion 5.58%
Narrow Range Bar Range Contraction 4.87%
NR7 Range Contraction 4.87%
Inside Day Range Contraction 4.87%
Bullish Engulfing Bullish 3.10%
Lower Bollinger Band Walk Weakness 3.10%
Earnings Movers Other 3.10%
Multiple of Ten Bullish Other 3.10%
Older End-of-Day Signals for SGMO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 2 hours ago
Rose Above Previous Day's High about 3 hours ago
Up 1% about 3 hours ago
Up 5% 3 days ago
60 Minute Opening Range Breakout 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sangamo BioSciences, Inc. Description

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Emerging Technologies Molecular Biology Blastoma Glioblastoma Hemoglobin Hemophilia Immunodeficiency Transcription Huntington's Disease Transcription Factors Cell Product Hemophilia A Monogenic Transcription Factor Hemoglobinopathies Lysosomal Storage Disorder Deficiency Syndrome Lysosomal Storage Disorders Monogenic Diseases Dow Agrosciences Hoffmann La Roche

Is SGMO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.43
52 Week Low 8.51
Average Volume 1,205,958
200-Day Moving Average 12.02
50-Day Moving Average 11.59
20-Day Moving Average 11.28
10-Day Moving Average 10.69
Average True Range 0.61
ADX 17.96
+DI 18.95
-DI 27.00
Chandelier Exit (Long, 3 ATRs ) 10.66
Chandelier Exit (Short, 3 ATRs ) 11.60
Upper Bollinger Band 12.69
Lower Bollinger Band 9.87
Percent B (%b) 0.35
BandWidth 25.00
MACD Line -0.37
MACD Signal Line -0.30
MACD Histogram -0.0645
Fundamentals Value
Market Cap 1.53 Billion
Num Shares 141 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -10.98
Price-to-Sales 8.57
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.68
Resistance 3 (R3) 11.62 11.28 11.54
Resistance 2 (R2) 11.28 11.06 11.31 11.50
Resistance 1 (R1) 11.06 10.93 11.17 11.13 11.45
Pivot Point 10.72 10.72 10.78 10.75 10.72
Support 1 (S1) 10.51 10.51 10.62 10.57 10.25
Support 2 (S2) 10.17 10.38 10.20 10.20
Support 3 (S3) 9.95 10.17 10.16
Support 4 (S4) 10.02